Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ivermectin: an award-winning drug with expected antiviral activity against COVID-19
Fábio Rocha Formiga, Roger LeBlanc, Juliana de Souza Rebouças, et al.
Journal of Controlled Release (2020) Vol. 329, pp. 758-761
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

Persistent SARS-CoV-2 Infection, EBV, HHV-6 and Other Factors May Contribute to Inflammation and Autoimmunity in Long COVID
Aristo Vojdani, Elroy Vojdani, Evan Saidara, et al.
Viruses (2023) Vol. 15, Iss. 2, pp. 400-400
Open Access | Times Cited: 81
Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes
Harpinder Kaur, Nishant Shekhar, Saurabh Sharma, et al.
Pharmacological Reports (2021) Vol. 73, Iss. 3, pp. 736-749
Open Access | Times Cited: 87
Exploring the Binding Efficacy of Ivermectin Against the Key Proteins of SARS-CoV-2 Pathogenesis: an in silico Approach
Abhigyan Choudhury, Nabarun Chandra Das, Ritwik Patra, et al.
Future Virology (2021) Vol. 16, Iss. 4, pp. 277-291
Open Access | Times Cited: 69
RBC-hitchhiking chitosan nanoparticles loading methylprednisolone for lung-targeting delivery
Yaning Ding, Bai Lv, Jinpeng Zheng, et al.
Journal of Controlled Release (2021) Vol. 341, pp. 702-715
Open Access | Times Cited: 67
The antiviral activity of iota-, kappa-, and lambda-carrageenan against COVID-19: A critical review
Andri Frediansyah
Clinical Epidemiology and Global Health (2021) Vol. 12, pp. 100826-100826
Open Access | Times Cited: 65
Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects
Slobodan Rendić
Archives of Toxicology (2021) Vol. 95, Iss. 5, pp. 1535-1546
Open Access | Times Cited: 47
Recent progress on the application of MOFs and their derivatives in adsorbing emerging contaminants
Ying Shen, Jiawei Kang, Luqi Guo, et al.
Separation and Purification Technology (2024) Vol. 350, pp. 127955-127955
Closed Access | Times Cited: 8
COVID-19: pathogenesis, advances in treatment and vaccine development and environmental impact—an updated review
Youssef A. Attia, Mohamed T. El‐Saadony, Ayman A. Swelum, et al.
Environmental Science and Pollution Research (2021) Vol. 28, Iss. 18, pp. 22241-22264
Open Access | Times Cited: 39
Nano-engineered tools in the diagnosis, therapeutics, prevention, and mitigation of SARS-CoV-2
Siya Kamat, Madhuree Kumari, Chelliah Jayabaskaran
Journal of Controlled Release (2021) Vol. 338, pp. 813-836
Open Access | Times Cited: 39
A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS‐CoV‐2
Robert T. Kinobe, Leigh Owens
Fundamental and Clinical Pharmacology (2021) Vol. 35, Iss. 2, pp. 260-276
Open Access | Times Cited: 37
Heterocyclic compounds as antiviral drugs: Synthesis, structure–activity relationship and traditional applications
Giovanny Carvalho dos Santos, Lucas Michelão Martins, Bruna Andressa Bregadiolli, et al.
Journal of Heterocyclic Chemistry (2021) Vol. 58, Iss. 12, pp. 2226-2260
Closed Access | Times Cited: 36
Red blood cell-hitchhiking mediated pulmonary delivery of ivermectin: Effects of nanoparticle properties
Jinpeng Zheng, Caihong Lu, Yaning Ding, et al.
International Journal of Pharmaceutics (2022) Vol. 619, pp. 121719-121719
Open Access | Times Cited: 26
Targeting furin, a cellular proprotein convertase, for COVID-19 prevention and therapeutics
Xia Jiang, Dabing Li, Mazaher Maghsoudloo, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 7, pp. 104026-104026
Closed Access | Times Cited: 6
Ivermectin for Prophylaxis and Treatment of COVID-19: A Systematic Review and Meta-Analysis
Mario Cruciani, Ilaria Pati, Francesca Masiello, et al.
Diagnostics (2021) Vol. 11, Iss. 9, pp. 1645-1645
Open Access | Times Cited: 32
Anti-COVID-19 Nanomaterials: Directions to Improve Prevention, Diagnosis, and Treatment
Mohammad Souri, Mohsen Chiani, Ali Akbar Farhangi, et al.
Nanomaterials (2022) Vol. 12, Iss. 5, pp. 783-783
Open Access | Times Cited: 22
Green and Smart Quantitative Quality Control for Veterinary Mixture of Ivermectin and Clorsulon: Ecological Evaluation of Spectral Analyses via Analytical Eco-Scale, Green Analytical Procedure Index, and Analytical GREEnness Metric Approaches
Miranda F. Kamal, Rasha M. Youssef, Samir Morshedy, et al.
Journal of AOAC International (2023) Vol. 106, Iss. 6, pp. 1455-1463
Closed Access | Times Cited: 13
Insights of phytoremediation mechanisms for viruses based on in-vitro, in-vivo and in-silico assessments of selected herbal plants
Diaiti Zure, Hsion-Wen Kuo, Aleksandra Drizo
Chemosphere (2024) Vol. 351, pp. 141101-141101
Closed Access | Times Cited: 4
Codelivery of ivermectin and methyl dihydrojasmonate in nanostructured lipid carrier for synergistic antileukemia therapy
Fatma S. Abou-Elnour, Salma E. El-Habashy, Marwa M. Essawy, et al.
International Journal of Pharmaceutics (2024) Vol. 656, pp. 124086-124086
Closed Access | Times Cited: 4
Emerging importance of nanotechnology-based approaches to control the COVID-19 pandemic; focus on nanomedicine iterance in diagnosis and treatment of COVID-19 patients
Behnam Hashemi, Akram Firouzi‐Amandi, Halimeh Amirazad, et al.
Journal of Drug Delivery Science and Technology (2021) Vol. 67, pp. 102967-102967
Open Access | Times Cited: 27
Virus-Induced Membrane Fusion in Neurodegenerative Disorders
Carolina Osorio, Adonis Sfera, Jonathan J. Anton, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 18
Ivermectin Protects Against Experimental Autoimmune Encephalomyelitis in Mice by Modulating the Th17/Treg Balance Involved in the IL-2/STAT5 Pathway
Yu Xie, Chaolei Jin, Hongzhen Sang, et al.
Inflammation (2023) Vol. 46, Iss. 5, pp. 1626-1638
Open Access | Times Cited: 10
Experimental Investigation into the Design, Optimization, Toxicity, and Anti-Viral Efficacy of Proliposomes Loaded with Ivermectin Against Infectious Bronchitis Virus Using an Embryonated Chicken Egg Model
Mohammad H. Alyami, Hamad S. Alyami, Asmaa M. Abdo, et al.
Pharmaceutics (2025) Vol. 17, Iss. 2, pp. 165-165
Open Access
Ivermectin-Induced Apoptotic Cell Death in Human SH-SY5Y Cells Involves the Activation of Oxidative Stress and Mitochondrial Pathway and Akt/mTOR-Pathway-Mediated Autophagy
Yuan Zhang, Tun Sun, Meng Li, et al.
Antioxidants (2022) Vol. 11, Iss. 5, pp. 908-908
Open Access | Times Cited: 16
Utility of sustainable ratio derivative spectrophotometry for the concurrent assay of synergistic repurposed drugs for COVID-19 infections; Insilico pharmacokinetics proof
Sara I. Aboras, Ahmed A. Megahed, Fawzy A. El‐Yazbi, et al.
BMC Chemistry (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 3
Outcomes of Ivermectin in the treatment of COVID-19: a systematic review and meta-analysis
Alex Castañeda-Sabogal, Diego Chambergo‐Michilot, Carlos J. Toro‐Huamanchumo, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top